Cannabinoid receptor CB1 inverse agonists - Pipeline Insight, 2022

“Cannabinoid Receptor CB1 Inverse Agonists - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cannabinoid Receptor CB1 Inverse Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Cannabinoid Receptor CB1 Inverse Agonists Understanding

Cannabinoid Receptor CB1 Inverse Agonists: Overview

The cannabinoid receptor 1 (CB1) is the most abundantly expressed G protein-coupled receptor (GPCR) in the brain. CB1 elicits its physiological responses by coupling primarily to Gi/o proteins to inhibit adenylate cyclase and cyclic AMP signaling.

Function – CB1R is encoded by the gene CNR1 and consists of 472 amino acids in humans (473 amino acids in rat and mouse, with 97–99% amino acid sequence identity among these species). The full-length CB1R dominates in the brain and skeletal muscle, whereas the CB1Rb (with 33 amino acid deletion at the N-terminus) shows a higher expression level in the liver and pancreatic islet cells where it is involved in metabolism.The CB1 receptor is a pre-synaptic heteroreceptor that modulates neurotransmitter release when activated in a dose-dependent, stereoselective and pertussis toxin-sensitive manner.The CB1 receptor is activated by cannabinoids, generated naturally inside the body (endocannabinoids) or introduced into the body as cannabis or a related synthetic compound.

Cannabinoid Receptor CB1 Inverse Agonists- Increased cortisol levels have been observed in patients suffering from a number of metabolic and psychiatric disorders. Cannabinoid Receptor CB1 Inverse Agonists which block cortisol effects might have a benefit in both the diagnosis and treatment of these disorders. These types of molecules inhibit the signal induced by the CB1 receptor, and even reverse its biological response (e.g.: no signal to seek food, signal to increase energy expenditure and speed up metabolism at rest, no fibrogenesis or even reverse fibrogenesis).

Cannabinoid Receptor CB1 Inverse Agonists Emerging Drugs Chapters

This segment of the Cannabinoid Receptor CB1 Inverse Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cannabinoid Receptor CB1 Inverse Agonists Emerging Drugs
• Cannabidiol: Stero Biotechs

STERO aims to solve an unmet need by using Cannabidiol (CBD), a non-psychotropic component of Cannabis sativa, which has been shown to possess potent immunomodulatory and anti-inflammatory properties in various indications. Preliminary results in a phase II trial in GVHD show that CBD administration enhanced the therapeutic effect of steroids or reduced the steroid dosage while maintaining or improving the steroid’s original therapeutic effect. The drug is in Phase II stage of development for the treatment of Autoimmune hepatitis; Crohn's disease; Graft-versus-host disease.
• INV-101: Inversago Pharma

INV-101 is a first-in-class, small molecule CB1 inverse agonist / antagonist being developed by Inversago for the treatment of PWS and NASH. It is specifically designed to interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. It has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 inverse agonist, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH).

Further product details are provided in the report……..

Cannabinoid Receptor CB1 Inverse Agonists: Therapeutic Assessment

This segment of the report provides insights about the different Cannabinoid Receptor CB1 Inverse Agonists drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Cannabinoid Receptor CB1 Inverse Agonists

There are approx. 15+ key companies which are developing the Cannabinoid Receptor CB1 Inverse Agonists. The companies which have their Cannabinoid Receptor CB1 Inverse Agonists drug candidates in the most advanced stage, i.e. Phase II include Stero Biotechs.
• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III )
• Mid-stage products (Phase II )
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Cannabinoid Receptor CB1 Inverse Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intravenous
• Intramuscular
• Oral
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cannabinoid Receptor CB1 Inverse Agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cannabinoid Receptor CB1 Inverse Agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cannabinoid Receptor CB1 Inverse Agonists drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Cannabinoid Receptor CB1 Inverse Agonists R&D.
• The therapies under development are focused on novel approaches for Cannabinoid Receptor CB1 Inverse Agonists.

Cannabinoid Receptor CB1 Inverse Agonists Report Insights
• Cannabinoid Receptor CB1 Inverse Agonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cannabinoid Receptor CB1 Inverse Agonists Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Cannabinoid Receptor CB1 Inverse Agonists drugs?
• How many Cannabinoid Receptor CB1 Inverse Agonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Cannabinoid Receptor CB1 Inverse Agonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cannabinoid Receptor CB1 Inverse Agonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cannabinoid Receptor CB1 Inverse Agonists and their status?
• What are the key designations that have been granted to the emerging drugs?